1. A method for identifying development of diabetic cardiovascular autonomic neuropathy (DCAN) in a biological subject, the method comprising:
collecting data associated with heart rates of a biological subject; and
processing the collected data to extract primary and secondary components of the collected data by performing a principal dynamic mode (PDM) analysis;
determine whether there is a significant reduction of the primary or secondary component at a predetermined time period;
wherein the significant reduction of the primary or secondary component at the predetermined time period is indicative of the DCAN development.
2. The method of claim 1, wherein the primary and secondary components respectively represent sympathetic and parasympathetic dynamics of an autonomic nervous system of the biological subject.
3. The method of claim 1, wherein collecting the data comprises monitoring pulsatile signals associated with the heart rates of the biological subject by detecting an optical property associated with a biological fluid of the biological subject using an imaging device of a portable communication device.
4. The method of claim 1, wherein collecting the data comprises monitoring pulsatile signals associated with the heart rates of the biological subject by using an electrocardiography (ECG) device.
5. The method of claim 1, wherein processing the collected data comprises using a computing device to:
detrend the collected data to obtain output data;
delay the detrended data by one unit to obtain input data;
form a principal matrix using Volterra kernels based on the input and the output; and
eigendecompose the principal matrix using a predetermined number of orthonormal functions as a basis to obtain eigenvalues and eigenvectors of the principal matrix.
6. The method of claim 5, wherein the primary and secondary, components respectively correspond to two of the eigenvectors associated with the first two greatest eigenvalues of the principal matrix.
7. The method of claim 5, wherein the orthonormal functions comprise Laguerre functions.
8. The method of claim 1, wherein collecting the data comprises collecting the data while the biological subject is at an active state; and wherein a significant reduction of the primary component is indicative of the DCAN development.
9. The method of claim 1, wherein collecting the data comprises collecting the data while the biological subject is at a quiet state; and wherein a significant reduction of the secondary component is indicative of the DCAN development.
10. A device for identifying development of diabetic cardiovascular autonomic neuropathy (DCAN) in a biological subject, the device comprising:
a processor configured to collect data associated with heart rates of a biological subject; and
a memory coupled to the processor to store the collected data;
wherein the processor is further configured to process the collected data to extract primary and secondary components of the collected data by performing a principal dynamic mode (PDM) analysis; and determine whether there is a significant reduction of the primary or secondary component at a predetermined time period; wherein the significant reduction of the primary or secondary component at the predetermined time period is indicative of the DCAN development.
11. The device of claim 10, wherein the primary and secondary components respectively represent sympathetic and parasympathetic dynamics of an autonomic nervous system of the biological subject.
12. The device of claim 10, further comprising an imaging device coupled to the processor, the imaging device being configured to obtain pulsatile signals associated with the heart rates of the biological subject.
13. The device of claim 12, wherein the imaging device is further configured to detect an optical property associated with a biological fluid of the biological subject so as to obtain the pulsatile signals.
14. The device of claim 10, further comprising an electrocardiography (ECG) device configured to obtain pulsatile, signals associated with the heart rates of the biological subject.
15. The device of claim 10, wherein the processor is further configured to:
detrend the collected data to obtain output data;
delay the detrended data by one unit to obtain input data;
form a principal matrix using Volterra kernels based on the input and the output; and
eigendecompose the principal matrix using a predetermined number of orthonormal functions as a basis to obtain eigenvalues and eigenvectors of the principal matrix.
16. The device of claim 15, wherein the primary and secondary components respectively correspond to two of the eigenvectors associated with the first two greatest eigenvalues of the principal matrix.
17. The device of claim 15, wherein the orthonormal functions comprise Laguerre functions.
18. The device of claim 10, wherein the processor is further configured to display an indication of the DCAN development, if the processor collects the data while the biological subject is at an active state, and if a significant reduction of the primary component occurs.
19. The device of claim 10, further comprising a display screen configured to display an indication of the DCAN development, if the processor collects the data while the biological subject is at a quiet state, and if a significant reduction of the secondary component occurs.
20. A system for identifying development of diabetic cardiovascular autonomic neuropathy (DCAN) in a biological subject comprising:
a mobile communication device comprising:
an imaging device, the imaging device being configured to obtain pulsatile signals associated with the heart rates of the biological subject;
a processor configured to collect data associated with heart rates of a biological subject; and
a memory coupled to the processor to store the collected data;
wherein the processor is further configured to process the collected data to extract primary and secondary components of the collected data by performing a principal dynamic mode (PDM) analysis; and determine whether there is a significant reduction of the primary or secondary component at a predetermined time period; the processor being operatively coupled to the imaging device and the memory;
wherein the significant reduction of the primary or secondary component at the predetermined time period is indicative of the DCAN development.
21. The system of claim 20 wherein the imaging device is further configured to detect an optical property associated with a biological fluid of the biological subject so as to obtain the pulsatile signals.
22. The system of claim 20 further comprising an electrocardiography (ECU) device configured to obtain pulsatile signals associated with the heart rates of the biological subject.
23. The system of claim 20 wherein the imaging device is further configured to obtain pulsatile signals associated with the heart rates of the biological subject.
24. The system of claim 20 wherein the processor is further configured to display an indication of the DCAN development, if the processor collects the data while the biological subject is at an active state, and if a significant reduction of the primary component occurs.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method comprising:
receiving a request for a first routable address associated with an alias address of a first called H.323 entity at a non-gatekeeper database external to a first domain in which the first called H.323 entity is located, the non-gatekeeper database external to a second domain in which a calling H.323 entity is located; and
providing the first routable address to a cache at a gatekeeper associated with the calling H.323 entity, the gatekeeper configured to remove a second routable address associated with a second called H.323 entity responsive to a cache policy and responsive to receiving the first routable address.
2. The method of claim 1, wherein the calling H.323 entity is visiting the second domain.
3. The method of claim 1, wherein the first called H.323 entity is visiting the first domain.
4. The method of claim 1, further comprising:
placing a call comprising multimedia communications responsive to receiving the first routable address.
5. The method of claim 1, further comprising:
registering the calling H.323 entity with the gatekeeper.
6. The method of claim 1, further comprising:
registering the calling H.323 entity in a home zone of a gatekeeper database.
7. The method of claim 1, further comprising:
registering the calling H.323 entity in a visitor zone of a gatekeeper database.
8. The method of claim 1, further comprising:
updating a home zone of a gatekeeper database associated the calling H.323 entity with information indicative of a location of the calling H.323 entity.
9. The method of claim 1, further comprising:
updating a home zone of a gatekeeper database associated the first called H.323 entity with information indicative of a location of the first called H.323 entity.
10. The method of claim 1, further comprising:
synchronizing the non-gatekeeper database with at least one other network database.
11. The method of claim 1, further comprising:
querying the non-gatekeeper database to obtain a current location of the first called H.323 entity.
12. The method of claim 1, further comprising:
caching the first routable address and the alias address of the first called H.323 entity at the gatekeeper associated with the calling H.323 entity.
13. The method of claim 1, further comprising:
caching the first routable address and the alias address of the first called H.323 entity at the gatekeeper associated with the calling H.323 entity responsive to the cache policy.
14. The method of claim 1, further comprising:
establishing the cache policy when the cache at the gatekeeper associated with the calling H.323 entity is full; and
caching the first routable address and the alias address of the first called H.323 entity in the cache responsive to the cache policy.
15. The method of claim 1, further comprising:
confirming that the alias address of the first called H.323 entity is portable.
16. The method of claim 1, further comprising:
responsive to a routable alias address, providing a billing rate to the calling H.323 entity for a multimedia communication.
17. The method of claim 1, further comprising:
determining a quality of service associated with the calling H.323 entity.
18. The method of claim 1, further comprising:
determining a quality of service associated with the calling H.323 entity; and
placing a multimedia call to the first routable address responsive to the quality of service associated with the calling H.323 entity.